| Today's Top Story |  |  | | - Report: Rare diseases are lucrative targets for drugmakers
Drugs to treat rare diseases are as economically viable as drugs to treat common diseases, thanks to incentives such as less-stringent clinical trial standards, according to a Thomson Reuters report. The data "substantiates the envisioned high returns on the R&D investment, particularly for drugs with multiple orphan disease approvals," said report co-author Kiran Meekings. PharmaTimes (U.K.) (8/23)        | Earn 3X rewards points when you fly with The Business Gold Rewards Card from American Express OPEN. Designed to earn Membership Rewards® points faster:
• 3X points on airfare
• 2X points on advertising, gas, and shipping
• 1X points on everything else
LEARN MORE AND APPLY |
  | Health Care & Policy | | | | - Study finds myeloma responds to donor stem cell transplant, Revlimid
 Donor stem cell transplant followed by Revlimid maintenance therapy can help patients whose multiple myeloma was nonresponsive or recurred after an autologous stem cell transplant, according to a German study published in the journal Bone Marrow Transplantation. Researchers said the treatment method was associated with a 13 percentage point decrease in relapse rate at three years as well as a low rate of treatment-related mortality. MyelomaBeacon.com (8/20) | Company & Financial News | | | | | Industry Deals | | | | - Pluristem extends stem cell treatment collaboration with German center
Pluristem Therapeutics and the Berlin-Brandenburg Center for Regenerative Therapy at Charite-University Medicine Berlin have agreed to continue their development of treatments based on placental stem cells. The agreement was extended for five years and now runs through 2017. The partners have worked on therapies for cardiovascular disease, multiple sclerosis and peripheral artery disease. Globes (Israel) (8/21)
| Food & Agriculture | | | | - Argentina working on new law to protect agri biotech patents
Argentina is drafting a law that would protect the patents of agricultural biotech products to help usher Monsanto's second-generation biotech soybean seeds into the country. "We're looking to protect intellectual property in the development process," agriculture minister Norberto Yauhar said. Monsanto, which was unable to patent its first-generation soybean seed in Argentina, plans to commercialize its second-generation herbicide- and insect-resistant soybeans in the country in 2014. Nasdaq.com/Dow Jones Newswires (8/22) | Industrial & Environmental | | | | | News from BIO | | | | - BIOtechNOW
BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter.
| SmartQuote | | | |  | Talent develops in quiet, Character in the torrent of the world."
--Johann Wolfgang von Goethe
German writer, artist and politician  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Wednesday, August 22, 2012
- Tuesday, August 21, 2012
- Monday, August 20, 2012
- Friday, August 17, 2012
- Thursday, August 16, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment